Background Follow-up of 131 I whole-body scanning after 131 I ablation is associated with
potential stunning. Previous studies have suggested that, for scanning, 123 I is more …

This study was performed to determine differences in 123I image quality at 5 and 24 h for the
detection of residual thyroid or recurrent disease in patients with differentiated thyroid cancer …

Objective To determine whether 123 I can be used as a safe and effective alternative tracer
to 131 I for imaging remnant tissue and for searching for metastatic lesions of well …

Background 123 I has been promoted for diagnostic imaging as a means of avoiding
'stunning'. It has also been suggested that the more favourable physical characteristics and …

OBJECTIVE Some patients with relapsed differentiated thyroid cancer may show rising
thyroglobulin (Tg) levels despite a lack of 131I uptake on routine whole body imaging. A …

Purpose Using 123 I for diagnostic purposes avoids the risk of stunning for subsequent
radioiodine treatment and affords an excellent image quality. In this study we assessed the …

The merits of 123I as a thyroid scanning agent have been lauded since it became possible
to produce 123I using a cyclotron. In 1967, Rhodes et al.(1) stated:“In the past, the …

Objective We assessed the performance of 37 MBq I-123 as a diagnostic imaging agent in
patients with differentiated thyroid cancer using comparisons with their corresponding high …

PURPOSE: To determine if stunning can be seen with a 185-MBq (5-mCi) dose of iodine
131 (131I) at diagnostic whole-body scanning and, if stunning is seen, determine if there is …

The use of 131I in doses of several mCi for scans can stun the thyrocytes and thyroid cancer
cells, whereas the usual dose (300 μCi) of 123I does not. We compared the diagnostic …